NAMSW NewAmsterdam Pharma Company N.V. - Warrant
$16,00
Precio · Ago 18, 2026
Fundamentales a fecha de Feb 18, 2026
Rango 52S
$13–$30
19% of range
Calificación del Analista
—
Precio Objetivo
—
P/E (TTM)
-9.3
ROE
-27.9%
Margen de Beneficio Neto
-905.7%
NAMSW Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$16.00
Capitalización Bursátil
$1.83B
P/E (TTM)
-9.3
BPA (TTM)
$-1.72
Ingresos (TTM)
$23M
Rendimiento div.
—
ROE
-27.9%
Deuda/Capital
—
Rango 52S
$13 – $30
NAMSW Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$23M
2022-12-31
→
2025-12-31
BPA
$-1.72
2021-12-31
→
2025-12-31
Flujo de caja libre
$-148M
2023-12-31
→
2025-12-31
Márgenes
-905.7%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
NAMSW
Mediana de Pares
P/E (TTM)
-9.3
—
P/S (TTM) (P/V (TTM))
81.3
—
P/B (P/C)
2.7
—
Price / FCF (Precio / FCF)
-12.4
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
NAMSW
Mediana de Pares
Operating Margin (Margen Operativo)
-1002.9%
—
Net Profit Margin (Margen de Beneficio Neto)
-905.7%
—
ROA
-24.9%
—
ROE
-27.9%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
NAMSW
Mediana de Pares
Current Ratio (Ratio corriente)
7.9
—
Quick Ratio (Ratio Rápido)
7.4
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
NAMSW
Mediana de Pares
Revenue YoY (Ingresos interanuales)
-50.6%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
-39.7%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
NAMSW
Mediana de Pares
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $23M | $46M | $14M | $103M | |
| R&D Expense | $142M | $151M | $159M | $87M | |
| SG&A Expense | $106M | $70M | $38M | $20M | |
| Operating Expenses | $248M | $222M | $197M | $106M | |
| Operating Income | $-226M | $-176M | $-183M | $-4M | |
| Interest Expense | · | · | · | $287.0K | |
| Interest Income | $28M | $17M | $11M | · | |
| Pretax Income | $-204M | $-242M | $-177M | $-23M | |
| Income Tax | · | $-1.0K | $27.0K | · | |
| Net Income | $-204M | $-242M | $-177M | $-23M | |
| EPS (Basic) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | |
| EPS (Diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | |
| Shares (Basic) | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | |
| Shares (Diluted) | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | |
| EBITDA | $-225M | $-176M | $-183M | · |
Balance general 16
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $490M | $772M | $340M | $468M | |
| Short-term Investments | $146M | $62M | · | · | |
| Prepaid Expense | $38M | $24M | $6M | $10M | |
| Current Assets | $676M | $863M | $347M | $478M | |
| PP&E (Net) | $383.0K | $242.0K | $46.0K | $34.0K | |
| Total Assets | $769M | $865M | $347M | $478M | |
| Accounts Payable | $9M | $5M | $17M | $12M | |
| Current Liabilities | $86M | $107M | $50M | $36M | |
| Capital Leases | $66.0K | $202.0K | · | $60.0K | |
| Total Liabilities | $86M | $107M | $59M | $48M | |
| Common Stock | $14M | $13M | $10M | $10M | |
| Retained Earnings | $-762M | $-559M | $-317M | $-140M | |
| AOCI | $5M | $4M | $4M | $4M | |
| Stockholders' Equity | $683M | $758M | $288M | $430M | |
| Liabilities + Equity | $769M | $865M | $347M | $478M | |
| Shares Outstanding | 114,399,326 | 108,064,340 | 82,469,768 | 81,559,780 |
Flujo de Efectivo 8
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $220.0K | $113.0K | $49.0K | $9.0K | |
| Stock-based Comp | $59M | $34M | $25M | $4M | |
| Other Non-cash | $-4M | $49M | $11M | · | |
| Operating Cash Flow | $-148M | $-159M | $-141M | $11M | |
| CapEx | $246.0K | $672.0K | $24.0K | $221.0K | |
| Investing Cash Flow | $-175M | $-63M | $-24.0K | $-221.0K | |
| Financing Cash Flow | $30M | $660M | $9M | $392M | |
| Free Cash Flow | $-148M | $-159M | $-141M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | -1002.9% | -386.9% | -1298.6% | · | |
| Net Margin | -905.7% | -530.2% | -1255.8% | · | |
| Pretax Margin | -905.7% | -530.2% | -1255.6% | · | |
| EBITDA Margin | -1001.9% | -386.7% | -1298.2% | · | |
| ROA | -24.9% | -39.9% | -42.9% | · | |
| ROE | -27.9% | -42.5% | -57.1% | · | |
| ROIC | · | -23.3% | -63.4% | · |
Liquidez y Solvencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 7.9 | 8.1 | 7.0 | · | |
| Quick Ratio | 7.4 | 7.8 | 6.8 | · |
Eficiencia 1
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.0 | · |
Tasas de Crecimiento 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | -50.6% | 223.4% | -86.3% | · | |
| Revenue CAGR 3Y | -39.7% | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $23M | $46M | $14M | · | |
| Net Income TTM | $-204M | $-242M | $-177M | · | |
| Market Cap | $2.63B | $1.54B | $258M | · | |
| P/E | -13.4 | -5.6 | -1.5 | · | |
| P/S | 116.9 | 33.8 | 18.3 | · | |
| P/B | 3.9 | 2.0 | 0.9 | · | |
| P / Tangible Book | 3.9 | 2.0 | 0.9 | · | |
| P / Cash Flow | -17.8 | -9.7 | -1.8 | · | |
| P / FCF | -17.8 | -9.7 | -1.8 | · | |
| Earnings Yield | -7.5% | -18.0% | -68.7% | · |
Estado de resultados 14
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0K | $348.0K | $19M | $3M | $13M | $29M | $2M | $1M | $803.0K | |
| R&D Expense | $39M | $31M | $28M | $45M | $35M | $36M | $38M | $42M | $41M | |
| SG&A Expense | $27M | $25M | $27M | $27M | $21M | $18M | $16M | $14M | $11M | |
| Operating Expenses | $66M | $55M | $55M | $72M | $56M | $54M | $55M | $57M | $52M | |
| Operating Income | $-66M | $-55M | $-36M | $-69M | $-43M | $-25M | $-53M | $-55M | $-51M | |
| Interest Income | $6M | $7M | $7M | $7M | $4M | $4M | $5M | $3M | $3M | |
| Pretax Income | $-75M | $-72M | $-17M | $-40M | $-92M | $-17M | $-39M | $-94M | $-49M | |
| Income Tax | · | · | · | · | $0 | $-1.0K | · | · | · | |
| Net Income | $-75M | $-72M | $-17M | $-40M | $-92M | $-17M | $-39M | $-94M | $-49M | |
| EPS (Basic) | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 | $-0.41 | $-1.06 | $-0.60 | |
| EPS (Diluted) | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 | $-0.41 | $-1.06 | $-0.60 | |
| Shares (Basic) | -235,257,468 | 119,000,266 | 118,556,492 | 116,124,941 | -183,487,907 | 94,754,140 | 94,711,604 | 88,380,230 | -164,003,575 | |
| Shares (Diluted) | -235,257,468 | 119,000,266 | 118,556,492 | 116,124,941 | -183,487,907 | 94,754,140 | 94,711,604 | 88,380,230 | -164,003,575 | |
| EBITDA | · | $-55M | $-36M | $-69M | · | $-25M | $-53M | $-55M | · |
Balance general 16
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $490M | $538M | $564M | $748M | $772M | $423M | $431M | $481M | $340M | |
| Short-term Investments | $146M | $165M | $175M | $60M | $62M | · | · | · | · | |
| Prepaid Expense | $38M | $28M | $31M | $9M | $24M | $15M | $15M | $7M | · | |
| Current Assets | $676M | $732M | $770M | $817M | $863M | $438M | $445M | $488M | · | |
| PP&E (Net) | $383.0K | $323.0K | $312.0K | $238.0K | $242.0K | $231.0K | $234.0K | $101.0K | · | |
| Total Assets | $769M | $786M | $815M | $818M | $865M | $439M | $447M | $488M | · | |
| Accounts Payable | $9M | $4M | $6M | $6M | $5M | $7M | $5M | $9M | · | |
| Current Liabilities | $86M | $58M | $37M | $41M | $107M | $41M | $45M | $60M | · | |
| Capital Leases | $66.0K | $85.0K | $103.0K | $137.0K | $202.0K | $266.0K | $328.0K | · | · | |
| Total Liabilities | $86M | $58M | $37M | $41M | $107M | $60M | $59M | $77M | · | |
| Common Stock | $14M | $14M | $14M | $14M | $13M | $11M | $11M | $11M | · | |
| Retained Earnings | $-762M | $-687M | $-615M | $-598M | $-559M | $-466M | $-450M | $-411M | · | |
| AOCI | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $4M | · | |
| Stockholders' Equity | $683M | $728M | $778M | $777M | $758M | $379M | $387M | $412M | $288M | |
| Liabilities + Equity | $769M | $786M | $815M | $818M | $865M | $439M | $447M | $488M | · | |
| Shares Outstanding | 114,399,326 | 113,172,684 | 112,509,914 | 112,169,291 | 108,064,340 | 92,165,605 | 90,015,357 | 89,720,836 | · |
Flujo de Efectivo 8
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $59.0K | $64.0K | $45.0K | $52.0K | $51.0K | $28.0K | $19.0K | $15.0K | $13.0K | |
| Stock-based Comp | $14M | $15M | $15M | $15M | $9M | $8M | $8M | $8M | $6M | |
| Other Non-cash | · | · | · | $-12M | · | · | · | $31M | · | |
| Operating Cash Flow | $-41M | $-33M | $-38M | $-36M | $-37M | $-13M | $-54M | $-55M | $-33M | |
| CapEx | $100.0K | $42.0K | $88.0K | $16.0K | $3.0K | $75.0K | $209.0K | $385.0K | $3.0K | |
| Investing Cash Flow | $-21M | $3M | $-159M | $3M | $-62M | $-75.0K | $-209.0K | $-385.0K | $-3.0K | |
| Financing Cash Flow | $14M | $6M | $3M | $7M | $457M | $58.0K | $5M | $198M | $0 | |
| Free Cash Flow | · | · | · | $-36M | · | · | · | $-55M | · |
Rentabilidad 7
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -15845.7% | -186.1% | -2314.5% | · | -85.9% | -2306.9% | -3960.2% | · | |
| Net Margin | · | -20691.1% | -90.7% | -1327.3% | · | -57.2% | -1711.6% | -6692.9% | · | |
| Pretax Margin | · | -20691.1% | -90.7% | -1327.3% | · | -57.2% | -1711.6% | -6692.9% | · | |
| EBITDA Margin | · | -15845.7% | -186.1% | -2312.7% | · | -85.9% | -2306.9% | -3959.1% | · | |
| ROA | · | -11.8% | -2.8% | -6.0% | · | -7.6% | -17.5% | -38.4% | · | |
| ROE | · | -13.0% | -3.0% | -6.7% | · | -8.8% | -20.1% | -45.5% | · | |
| ROIC | · | · | · | · | · | -6.6% | · | · | · |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 12.6 | 21.1 | 20.0 | · | 10.6 | 9.8 | 8.2 | · | |
| Quick Ratio | · | 12.1 | 20.2 | 19.8 | · | 10.2 | 9.5 | 8.1 | · |
Eficiencia 1
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · |
Valoración (TTM) 10
| Métrica | Tendencia | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $52M | $54M | $36M | · | $36M | $8M | $15M | · | |
| Net Income TTM | · | $-146M | $-113M | $-189M | · | $-197M | $-218M | $-221M | · | |
| Market Cap | · | $1.94B | $900M | $1.01B | · | $645M | $785M | $991M | · | |
| P/E | · | -13.4 | -7.4 | -4.5 | · | -3.2 | -3.5 | -4.2 | · | |
| P/S | · | 37.5 | 16.8 | 28.2 | · | 18.1 | 94.1 | 67.4 | · | |
| P/B | · | 2.7 | 1.2 | 1.3 | · | 1.7 | 2.0 | 2.4 | · | |
| P / Tangible Book | · | 2.7 | 1.2 | 1.3 | · | 1.7 | 2.0 | 2.4 | · | |
| P / Cash Flow | · | · | · | -27.7 | · | · | · | -18.1 | · | |
| P / FCF | · | · | · | -27.6 | · | · | · | -18.0 | · | |
| Earnings Yield | · | -7.5% | -13.5% | -22.1% | · | -31.7% | -28.8% | -23.6% | · |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $23M | $46M | $14M | $103M | — |
| Margen Operativo % | -1002.9% | -386.9% | -1298.6% | — | — |
| Beneficio neto | $-204M | $-242M | $-177M | $-23M | $-42M |
| EPS Diluido | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 7.9 | 8.1 | 7.0 | — | — |
| Ratio Rápido | 7.4 | 7.8 | 6.8 | — | — |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-148M | $-159M | $-141M | — | — |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 11 declarantes · $29.6M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 0 (-1 vs trimestre anterior) | 0 (0 vs trimestre anterior) | 2 (+2 vs trimestre anterior) | 0 (-1 vs trimestre anterior) | +13K |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $10 692 116 | 500 333 | 36,15% | Acciones |
| RA CAPITAL MANAGEMENT, L.P. | $7 123 326 | 333 333 | 24,09% | Acciones |
| Affinity Asset Advisors, LLC | $5 343 450 | 245 000 | 18,07% | Acciones |
| Bain Capital Life Sciences Investors, LLC | $2 136 979 | 99 999 | 7,23% | Acciones |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $1 982 858 | 92 787 | 6,70% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $1 602 750 | 75 000 | 5,42% | Opción de compra |
| ARISTEIA CAPITAL, L.L.C. | $343 377 | 15 708 | 1,16% | Acciones |
| WOLVERINE ASSET MANAGEMENT LLC | $318 947 | 14 925 | 1,08% | Acciones |
| CIBC Private Wealth Group LLC | $22 388 | 1 250 | 0,08% | Acciones |
| UBS Group AG | $8 523 | 443 | 0,03% | Acciones |
| Vestcor Inc | $143 | 6 666 | 0,00% | Acciones |
Informantes de la empresa 1 insider · 1 directivos · 0 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Louise Frederika Kooij | Chief Accounting Officer | 20 de julio de 2026 M | 24 353 | 0 | 5 | $-4 393 815 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| BCLS Fund III Investments, LP, Bain Capital Life Sciences Opportunities III, LP, Bain Capital Life Sciences Fund II, L.P., BCLS II Investco, LP, BCLS II Equity Opportunities, LP, BCIP Life Sciences Associates, LP | 14 de mayo de 2026 | 1,76% | Enmienda | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.